Association of disease progression, health-related quality of life (HRQoL), and utility in patients (pts) with advanced, nonfunctional, well-differentiated gastrointestinal (GI) or lung neuroendocrine tumors (NET) in the phase 3 RADIANT-4 trial.

Abstract

4093Background: Post hoc analyses were performed to determine if disease progression is associated with decline in HRQoL and utility scores using data from RADIANT-4, a phase 3 trial that showed si...